Shire Plc’s positive study for a dry-eye disease drug will help boost the company’s attempt to buy Baxalta Inc., Chief Executive Officer Flemming Ornskov said in an interview.
The trial, dubbed Opus-3, met its primary goal of reducing symptoms of dry eye disease, Shire said Tuesday. That paves the way for a refiling of lifitegrast with U.S. regulators next quarter. Analysts expect sales of the drug to exceed $700 million by 2020.
Help employers find you! Check out all the jobs and post your resume.
